SWOG Cancer Research Network

SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.

[David Gandara @drgandara]

MAVERICK trial. This KM curve says it all. It's RIP for PCI in SCLC. @SWOG

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

Great Work! MRI Surveillance carried less risks of cognitive impairment without difference in OS in patients with SCLC!
Congratulations! #S1827 @SWOG @IASLC #WCLC26

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm

[SWOG Cancer Research Network @SWOG]

Read more about this new TrialMatch AI-assisted tool for finding cancer clinical trials for patients -- and about the study underway with @theMedNet and @SWOG testing whether the tool can raise awareness of trials and increase referrals:
https://t.co/frnsrvpTVC

[Dr. Anthony Letai @NCIDirector]

I am committed to reducing administrative burdens related to cancer clinical trials. NCI SBIR-funded @theMedNet is helping with TrialMatch, a new AI-assisted tool that makes it faster and easier for doctors to find trials for their patients. https://t.co/x5pGgLFlpV

[Dr. Anthony Letai @NCIDirector]

I am committed to reducing administrative burdens related to cancer clinical trials. NCI SBIR-funded @theMedNet is helping with TrialMatch, a new AI-assisted tool that makes it faster and easier for doctors to find trials for their patients. https://t.co/x5pGgLFlpV

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

I can’t wait to learn about the results of #S1827 in the presidential session on the first day of #WCLC2026 @IASLC @SWOG #PCI in Limited Stage SCLC & Extensive Stage SCLC Benefits, neurotoxicity, Early detection of lesions, role of MRI & SRS all are important questions.

[SWOG Cancer Research Network @SWOG]

Ovarian reserve as measure of adjuvant chemotherapy benefit in HR-positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
In premenopausal pts <55yrs, AMH was significantly better indicator of chemo benefit than menopause status, age
https://t.co/dxBTZeA3qM

[SWOG Cancer Research Network @SWOG]

Federal and Industry Sponsorship in US Cancer Clinical Trials
A comparative study of cancer clinical trial portfolios supported by federal versus industry funding characterizes their distinct, interdependent roles. In @JAMAOncology @drjoeunger @fredhutch
https://t.co/rlQ13gavNd

[Annals of Oncology @Annals_Oncology]

🔥Measures of ovarian reserve could help refine selection to chemotherapy for patients with HR+, HER2-neg eBC
👉In RxPONDER, among premenopausal patients aged<55, those with low AMH levels did not benefit from chemotherapy
https://t.co/2fN0ksG0rZ

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm

[Julie Gralow @jrgralow]

Final day of @SWOG Latin America Initiative @incanMX @SMEOMX symposium in Precision Oncology Research, Methods, and Data symposium in Mexico City. Congrats to the students and early career researchers selected to present their clinical trials proposals for in depth review and discussion! @Betzabe100 @anelcabrera

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm

[NRG Oncology @NRGonc]

The COMMIT Trial NRG-GI004 @SWOG S1610: Combination immunotherapy and chemotherapy improves progression-free survival for patients with metastatic dMMR colorectal cancer, via @EurekAlert! https://t.co/Rf5zyYWyZf @JCO_ASCO

[Sia Daneshmand, M.D. @siadaneshmand]

New in @JAMANetworkOpen: @SWOG S1600, a multicenter phase 3 RCT, found no reduction in 30- or 90-day complications w/ specialized immunonutrition vs standard nutrition after cystectomy. Exploratory DFS/OS favored immunonutrition. #BladderCancer
@JhamiltonReeves @DrJoeUnger @JMHolzbeierlein @FoxChaseCancer @BCM_Urology @JanetKukreja @eugenekanglee @URMCUrology @DrDawnHershman @fischmd @lynnhenrymd https://t.co/671sdA0D1y

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

Team effort! @SWOG @WinshipAtEmory

[Lung-MAP @LungMAP]

"If you're MET amplified, you could well consider S1900J ... That's for patients who have MET amplification at initial genomic testing."
- Marcia Horn, Chair, @METCrusaders
@LungMAP is a precision medicine trial testing treatments for advanced non-small cell lung cancer.
#NSCLC

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm

[David Gandara @drgandara]

On this issue of ICI monotherapy versus combination with chemotherapy, the recently completed ECOG-SWOG phase 3 trial INSIGNA directly addresses this question in a randomized fashion. Also includes the PDL1 1-49% group Data analysis pending. @HosseinBorghaei @Annechiangmd @SWOG

[Sia Daneshmand, M.D. @siadaneshmand]

Let’s not forget the BRIGHT trial (@SWOG S2427) -Phase II study evaluating a bladder-preservation strategy for patients with #MIBC who achieve a meaningful response to neoadjuvant therapy—using pembrolizumab + radiation instead of immediate radical cystectomy in carefully selected patients. @l_ballas @AbhiTrip87 @MarkTysonMD @mouwlab @JoshMeeks @djmcconkey @KyleRoseMD @DrKarineTawagi @SeanSachdevMD @kritimittalmd